Challenges for molecular neuroimaging with MRI

International Journal of Imaging Systems and Technology

Volumn 20, Issue 1, 2010, Pages 71-79

  Lelyveld, Victor S ^a   Atanasijevic, Tatjana ^a   Jasanoff, Alan ^a  

^a Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

Brain; Contrast agent; Molecular; MRI; Neuroimaging

Indexed keywords

BLOOD-BRAIN BARRIER; BRAIN DELIVERY; CENTRAL NERVOUS SYSTEMS; CONTRAST AGENT; IN-VITRO; LONGITUDINAL RELAXATION TIME; MOLECULAR; MOLECULAR IMAGING; MOLECULAR LEVELS; MOLECULAR SIGNALS; MRI CONTRAST AGENTS; NEURO-IMAGING; RELAXIVITY; SIDE EFFECT; TRANSVERSE RELAXATION TIME;

ANIMALS; NEUROPHYSIOLOGY; RESONANCE;

RELAXATION PROCESSES;

EID: 77449108100     PISSN: 08999457     EISSN: 10981098     Source Type: Journal    
DOI: 10.1002/ima.20221     Document Type: Article

References (121)

1. S. Aime, M. Botta, S.G. Crich, G. Giovenzana, R. Pagliarin, M. Sisti, and E. Terreno, NMR relaxometric studies of Gd(III) complexes with heptadentate macrocyclic ligands, Magn Reson Chem 36 (1998), S200-S208.
2. S. Aime, D.D. Castelli, S.G. Crich, E. Gianolio, and E. Terreno, Pushing the sensitivity envelope of lanthanide-based magnetic resonance imaging (MRI) contrast agents for molecular imaging applications, Acc Chem Res 42 (2009), 822-831.
3. M.J. Allen, K.W. MacRenaris, P.N. Venkatasubramanian, and T.J. Meade, Cellular delivery of MRI contrast agents, Chem Biol 11 (2004), 301-307.
4. M.J. Allen and T.J. Meade, Magnetic resonance contrast agents for medical and molecular imaging, Met Ions Biol Syst 42 (2004), 1-38.
5. I. Aoki, C. Tanaka, T. Takegami, T. Ebisu, M. Umeda, M. Fukunaga, K. Fukuda, A.C. Silva, A.P. Koretsky, and S. Naruse, Dynamic activityinduced manganese-dependent contrast magnetic resonance imaging (DAIM MRI), Magn Reson Med 48 (2002), 927-933.
6. J.H. Ardenkjaer-Larsen, B. Fridlund, A. Gram, G. Hansson, L. Hansson, M.H. Lerche, R. Servin, M. Thaning, and K. Golman, Increase in signal-tonoise ratio of >10, 000 times in liquid-state NMR, Proc Natl Acad Sci USA 100 (2003), 10158-10163.
7. L. Bakay, H.T. Ballantine Jr., T.F. Hueter, and D. Sosa, Ultrasonically produced changes in the blood-brain barrier, AMA Arch Neurol Psychiatry 76 (1956), 457-467.
8. H.T. Ballantine Jr., E. Bell, and J. Manlapaz, Progress and problems in the neurological applications of focused ultrasound, J Neurosurg 17 (1960), 858-876.
9. S. Berger, L. Schurer, R. Hartl, K. Messmer, and A. Baethmann, Reduction of post-traumatic intracranial hypertension by hypertonic/hyperoncotic saline/dextran and hypertonic mannitol, Neurosurgery 37 (1995), 98-107; discussion 107-108.
10. A. Bogdanov Jr., L. Matuszewski, C. Bremer, A. Petrovsky, and R. Weissleder, Oligomerization of paramagnetic substrates result in signal amplification and can be used for MR imaging of molecular targets, Mol Imaging 1 (2002), 16-23.
11. S. Boutry, C. Burtea, S. Laurent, G. Toubeau, L. Vander Elst, and R.N. Muller, Magnetic resonance imaging of inflammation with a specific selectintargeted contrast agent, Magn Reson Med 53 (2005), 800-807.
12. E. Brunner, M. Haake, L. Kaiser, A. Pines, and J.A. Reimer, Gas flow MRI using circulating laser-polarized 129Xe, J Magn Reson 138 (1999), 155-159.
13. W.P. Cacheris, S.C. Quay, and S.M. Rocklage, The relationship between thermodynamics and the toxicity of gadolinium complexes, Magn Reson Imaging 8 (1990), 467-481.
14. P. Caravan, J.J. Ellison, T.J. McMurry, and R.B. Lauffer, Gadolinium(III) chelates as MRI contrast agents: Structure, dynamics, and applications, Chem Rev 99 (1999), 2293-2352.
15. P. Caravan, C.T. Farrar, L. Frullano, and R. Uppal, Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganese-based T1 contrast agents, Contrast Media Mol Imaging 4 (2009), 89-100.
16. S.V. Chandra and G.S. Shukla, Role of iron deficiency in inducing susceptibility to manganese toxicity, Arch Toxicol 35 (1976), 319-323.
17. J.J. Choi, M. Pernot, T.R. Brown, S.A. Small, and E.E. Konofagou, Spatiotemporal analysis of molecular delivery through the blood-brain barrier using focused ultrasound, Phys Med Biol 52 (2007), 5509-5530.
18. B. Cohen, K. Ziv, V. Plaks, and T. Israely, MRI detection of transcriptional regulation of gene expression in transgenic mice, Nat Med 13 (2007), 498-503.
19. S.M. Cohen, J. Xu, E. Radkov, K.N. Raymond, M. Botta, A. Barge, and S. Aime, Syntheses and relaxation properties of mixed gadolinium hydroxypyridinonate MRI contrast agents, Inorg Chem 39 (2000), 5747-5756.
20. C.H. Cunningham, T. Arai, P.C. Yang, M.V. McConnell, J.M. Pauly, and S.M. Conolly, Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles, Magn Reson Med 53 (2005), 999-1005.
21. A. Datta, J.M. Hooker, M. Botta, M.B. Francis, S. Aime, and K.N. Raymond, High relaxivity gadolinium hydroxypyridonate-viral capsid conjugates: Nanosized MRI contrast agents, J Am Chem Soc 130 (2008), 2546-2552.
22. L.M. de Leon-Rodriguez, A.J. Lubag, C.R. Malloy, G.V. Martinez, R.J. Gillies, and A.D. Sherry, Responsive MRI agents for sensing metabolism in vivo, Acc Chem Res 42 (2009), 948-957.
23. A.E. Dementyev, D.G. Cory, and C. Ramanathan, Dynamic nuclear polarization in silicon microparticles, Phys Rev Lett 100 (2008), 127601.
24. G.P. Dietz and M. Bahr, Delivery of bioactive molecules into the cell: The Trojan horse approach, Mol Cell Neurosci 27 (2004), 85-131.
25. N.M. Elkassabany, J. Bhatia, A. Deogaonkar, G.H. Barnett, M. Lotto, M. Maurtua, Z. Ebrahim, A. Schubert, S. Ference, and E. Farag, Perioperative complications of blood brain barrier disruption under general anesthesia: A retrospective review, J Neurosurg Anesthesiol 20 (2008), 45-48.
26. F.A. Gallagher, M.I. Kettunen, S.E. Day, D.E. Hu, J.H. Ardenkjaer-Larsen, R. Zandt, P.R. Jensen, M. Karlsson, K. Golman, M.H. Lerche, and K.M. Brindle, Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate, Nature 453 (2008), 940-943.
27. M.L. Garcia-Martin, G.V. Martinez, N. Raghunand, A.D. Sherry, S. Zhang, and R.J. Gillies, High resolution pH(e) imaging of rat glioma using pH-dependent relaxivity, Magn Reson Med 55 (2006), 309-315.
28. G. Genove, U. DeMarko, H. Xu, W.F. Goins, and E.T. Ahrens, A new transgene reporter for in vivo magnetic resonance imaging, Nat Med 11 (2005), 450-454.
29. C.F. Geraldes, A.D. Sherry, P. Vallet, F. Maton, R.N. Muller, T.D. Mody, G. Hemmi, and J.L. Sessler, Nuclear magnetic relaxation dispersion studies of water-soluble gadolinium(III)-texaphyrin complexes, J Magn Reson Imaging 5 (1995), 725-729.
30. A.A. Gilad, M.T. McMahon, P. Walczak, P.T. Winnard Jr., V. Raman, H.W. van Laarhoven, C.M. Skoglund, J.W. Bulte, and P.C. van Zijl, Artificial reporter gene providing MRI contrast based on proton exchange, Nat Biotechnol 25 (2007), 217-219.
31. A.A. Gilad, K. Ziv, M.T. McMahon, P.C. van Zijl, M. Neeman, and J.W. Bulte, MRI reporter genes, J Nucl Med 49 (2008), 1905-1908.
32. D.E. Goldhawk, C. Lemaire, C.R. McCreary, R. McGirr, S. Dhanvantari, R.T. Thompson, R. Figueredo, J. Koropatnick, P. Foster, and F.S. Prato, Magnetic resonance imaging of cells overexpressing MagA, an endogenous contrast agent for live cell imaging, Mol Imaging 8 (2009), 129-139.
33. K. Golman, R. In't Zandt, and M. Thaning, Real-time metabolic imaging, Proc Natl Acad Sci USA 103 (2006), 11270-11275.
34. A.E. Gulyaev, S.E. Gelperina, I.N. Skidan, A.S. Antropov, G.Y. Kivman, and J. Kreuter, Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles, Pharm Res 16 (1999), 1564-1569.
35. T.J. Harris, G. von Maltzahn, A.M. Derfus, E. Ruoslahti, and S.N. Bhatia, Proteolytic actuation of nanoparticle self-assembly, Angew Chem Int Ed Engl 45 (2006), 3161-3165.
36. B.T. Hawkins and T.P. Davis, The blood-brain barrier/neurovascular unit in health and disease, Pharmacol Rev 57 (2005), 173-185.
37. F. Helmchen and D. Tank, "A single-compartment model of calcium dynamics in nerve terminals and dendrites, " Imaging in neuroscience and development: A laboratory manual, R. Yuste and A. Konnerth (Editors), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2005, pp. 265-275.
38. M. Higuchi, N. Iwata, Y. Matsuba, K. Sato, K. Sasamoto, and T.C. Saido, 19F and 1H MRI detection of amyloid beta plaques in vivo, Nat Neurosci 8 (2005), 527-533.
39. C. Hilty, T.J. Lowery, D.E. Wemmer, and A. Pines, Spectrally resolved magnetic resonance imaging of a xenon biosensor, Angew Chem Int Ed Engl 45 (2005), 70-73.
40. J. Huwyler, D. Wu, and W.M. Pardridge, Brain drug delivery of small molecules using immunoliposomes, Proc Natl Acad Sci USA 93 (1996), 14164- 14169.
41. K. Hynynen, N. McDannold, N.A. Sheikov, F.A. Jolesz, and N. Vykhodtseva, Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications, Neuroimage 24 (2005), 12-20.
42. K. Hynynen, N. McDannold, N. Vykhodtseva, and F.A. Jolesz, Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits, Radiology 220 (2001), 640-646.
43. K. Hynynen, N. McDannold, N. Vykhodtseva, S. Raymond, R. Weissleder, F.A. Jolesz, and N. Sheikov, Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: A method for molecular imaging and targeted drug delivery, J Neurosurg 105 (2006), 445-454.
44. A. Jasanoff, MRI contrast agents for functional molecular imaging of brain activity, Curr Opin Neurobiol 17 (2007), 593-600.
45. L. Josephson, C.H. Tung, A. Moore, and R. Weissleder, High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates, Bioconjug Chem 10 (1999), 186-191.
46. 2+) inverse spinel ferrites for potential use as phase-contrast agents in medical MRI, J Magn Magn Mater 321 (2009), 3899-3904.
47. M. Kinoshita, N. McDannold, F.A. Jolesz, and K. Hynynen, Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption, Proc Natl Acad Sci USA 103 (2006), 11719-11723.
48. R.A. Kroll, M.A. Pagel, L.L. Muldoon, S. Roman-Goldstein, S.A. Fiamengo, and E.A. Neuwelt, Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: A comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers, Neurosurgery 43 (1998), 879-886; discussion 886-879.
49. P.H. Kuo, E. Kanal, A.K. Abu-Alfa, and S.E. Cowper, Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis, Radiology 242 (2007), 647-649.
50. R.E. Lauffer, Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: Theory and design, Chem Rev 87 (1987), 901-927.
51. S. Laurent, L.V. Elst, and R.N. Muller, Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents, Contrast Media Mol Imaging 1 (2006), 128-137.
52. P.C. Lauterbur, Progress in n.m.r. zeugmatography imaging, Philos Trans R Soc Lond B Biol Sci 289 (1980), 483-487.
53. H.J. Lee, Y. Zhang, C. Zhu, K. Duff, and W.M. Pardridge, Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical, J Cereb Blood Flow Metab 22 (2002), 223- 231.
54. J.-H. Lee, Y.-M. Huh, Y.-W. Jun, J.-W. Seo, J.-T. Jang, H.-T. Song, S. Kim, E.-J. Cho, H.-G. Yoon, J.-S. Suh, and J. Cheon, Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging, Nat Med 13 (2007), 95-99.
55. 2: Dose-dependent and temporal evolution of T1 contrast, Magn Reson Med 53 (2005), 640-648.
56. F.P. Leite, D. Tsao, W. Vanduffel, D. Fize, Y. Sasaki, L.L. Wald, A.M. Dale, K.K. Kwong, G.A. Orban, B.R. Rosen, R.B. Tootell, and J.B. Mandeville, Repeated fMRI using iron oxide contrast agent in awake, behaving macaques at 3 Tesla, Neuroimage 16 (2002), 283-294.
57. M. Lepage, W.C. Dow, M. Melchior, Y. You, B. Fingleton, C.C. Quarles, C. Pepin, J.C. Gore, L.M. Matrisian, and J.O. McIntyre, Noninvasive detection of matrix metalloproteinase activity in vivo using a novel magnetic resonance imaging contrast agent with a solubility switch, Mol Imaging 6 (2007), 393-403.
58. Y.J. Lin and A.P. Koretsky, Manganese ion enhances T1-weighted MRI during brain activation: An approach to direct imaging of brain function, Magn Reson Med 38 (1997), 378-388.
59. C.H. Liu, Y.R. Kim, J.Q. Ren, F. Eichler, B.R. Rosen, and P.K. Liu, Imaging cerebral gene transcripts in live animals, J Neurosci 27 (2007), 713-722.
60. H.L. Liu, P.H. Hsu, P.C. Chu, Y.Y. Wai, J.C. Chen, C.R. Shen, T.C. Yen, and J.J. Wang, Magnetic resonance imaging enhanced by superparamagnetic iron oxide particles: Usefulness for distinguishing between focused ultrasound- induced blood-brain barrier disruption and brain hemorrhage, J Magn Reson Imaging 29 (2009), 31-38.
61. M. Longmire, P.L. Choyke, and H. Kobayashi, Clearance properties of nano-sized particles and molecules as imaging agents: Considerations and caveats, Nanomed 3 (2008), 703-717.
62. A.Y. Louie, M.M. Hüber, E.T. Ahrens, U. Rothbächer, R. Moats, R.E. Jacobs, S.E. Fraser, and T.J. Meade, In vivo visualization of gene expression using magnetic resonance imaging, Nat Biotechnol 18 (2000), 321-325.
63. V. Mani, K.C. Briley-Saebo, V.V. Itskovich, D.D. Samber, and Z.A. Fayad, Gradient echo acquisition for superparamagnetic particles with positive contrast (GRASP): Sequence characterization in membrane and glass superparamagnetic iron oxide phantoms at 1.5T and 3T, Magn Reson Med 55 (2006), 126-135.
64. S. Mansson, E. Johansson, P. Magnusson, C.M. Chai, G. Hansson, J.S. Petersson, F. Stahlberg, and K. Golman, 13C imaging-a new diagnostic platform, Eur Radiol 16 (2006), 57-67.
65. Y. Mardor, O. Rahav, Y. Zauberman, Z. Lidar, A. Ocherashvilli, D. Daniels, Y. Roth, S.E. Maier, A. Orenstein, and Z. Ram, Convection-enhanced drug delivery: Increased efficacy and magnetic resonance image monitoring, Cancer Res 65 (2005), 6858-6863.
66. E.R. McCarney, B.D. Armstrong, M.D. Lingwood, and S. Han, Hyperpolarized water as an authentic magnetic resonance imaging contrast agent, Proc Natl Acad Sci USA 104 (2007), 1754-1759.
67. M.T. McMahon, A.A. Gilad, M.A. DeLiso, S.M. Berman, J.W. Bulte, and P.C. van Zijl, New "multicolor" polypeptide diamagnetic chemical exchange saturation transfer (DIACEST) contrast agents for MRI, Magn Reson Med 60 (2008), 803-812.
68. T.J. Meade, A.K. Taylor, and S.R. Bull, New magnetic resonance contrast agents as biochemical reporters, Curr Opin Neurobiol 13 (2003), 597-602.
69. Z. Medarova, W. Pham, C. Farrar, V. Petkova, and A. Moore, In vivo imaging of siRNA delivery and silencing in tumors, Nat Med 13 (2007), 372- 377.
70. P.H. Mills and E.T. Ahrens, Enhanced positive-contrast visualization of paramagnetic contrast agents using phase images, Magn Reson Med 62 (2009), 1349-1355.
71. R.A. Moats, S.E. Fraser, and T.J. Meade, A "smart" magnetic resonance imaging agent that reports on specific enzyme activity, Angew Chem Int Ed Engl 36 (1997), 726-728.
72. B.A. Moffat, G.R. Reddy, P. McConville, D.E. Hall, T.L. Chenevert, R.R. Kopelman, M. Philbert, R. Weissleder, A. Rehemtulla, and B.D. Ross, A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI, Mol Imaging 2 (2003), 324-332.
73. L.L. Muldoon, M. Sandor, K.E. Pinkston, and E.A. Neuwelt, Imaging, distribution, and toxicity of superparamagnetic iron oxide magnetic resonance nanoparticles in the rat brain and intracerebral tumor, Neurosurgery 57 (2005), 785-796; discussion 785-796.
74. R.N. Muller, A. Roch, J.-M. Colet, A. Ouakssim, and P. Gillis, "Particulate magnetic contrast agents, " The chemistry of contrast agents in medical magnetic resonance imaging, A.E. Merbach and E. Toth (Editors), Wiley, New York, 2001.
75. E.A. Neuwelt, E. Balaban, J. Diehl, S. Hill, and E. Frenkel, Successful treatment of primary central nervous system lymphomas with chemotherapy after osmotic blood-brain barrier opening, Neurosurgery 12 (1983), 662- 671.
76. E.A. Neuwelt and S.I. Rapoport, Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors, Fed Proc 43 (1984), 214-219.
77. A.B. Norman, K.J. Bertram, S.R. Thomas, R.G. Pratt, R.C. Samaratunga, and P.R. Sanberg, Magnetic resonance imaging of rat brain following in vivo disruption of the cerebral vasculature, Brain Res Bull 26 (1991), 593- 597.
78. S. Ogawa, T. Lee, A. Kay, and D. Tank, Brain magnetic resonance imaging with contrast dependent on blood oxygenation, Proc Natl Acad Sci USA 87 (1990), 9868-9872.
79. C.W. Olanow, Manganese-induced parkinsonism and Parkinson's disease, Ann NY Acad Sci 1012 (2004), 209-223.
80. W.M. Pardridge, Blood-brain barrier drug targeting: The future of brain drug development, Mol Interv 3 (2003), 90-105, 151.
81. W.M. Pardridge, The blood-brain barrier: Bottleneck in brain drug development, NeuroRx 2 (2005), 3-14.
82. W.M. Pardridge, Drug targeting to the brain, Pharm Res 24 (2007), 1733- 1744.
83. W.M. Pardridge, Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses, Bioconjug Chem 19 (2008), 1327-1338.
84. R.G. Pautler, A.C. Silva, and A.P. Koretsky, In vivo neuronal tract tracing using manganese-enhanced magnetic resonance imaging, Magn Reson Med 40 (1998), 740-748.
85. B. Perlstein, Z. Ram, D. Daniels, A. Ocherashvilli, Y. Roth, S. Margel, and Y. Mardor, Convection-enhanced delivery of maghemite nanoparticles: Increased efficacy and MRI monitoring, Neuro Oncol 10 (2008), 153-161.
86. M. Phelps, E. Hoffmann, N. Mullani, and M. Ter-Pogossian, Application of annihilation coincidence detection to transaxial reconstruction tomography, J Nucl Med 16 (1975), 210-224.
87. V.C. Pierre, M. Botta, and K.N. Raymond, Dendrimeric gadolinium chelate with fast water exchange and high relaxivity at high magnetic field strength, J Am Chem Soc 127 (2005), 504-505.
88. P. Porcari, S. Capuani, E. D'Amore, M. Lecce, A. La Bella, F. Fasano, R. Campanella, L.M. Migneco, F.S. Pastore, and B. Maraviglia, In vivo (19)F MRI and (19)F MRS of (19)F-labelled boronophenylalanine-fructose complex on a C6 rat glioma model to optimize boron neutron capture therapy (BNCT), Phys Med Biol 53 (2008), 6979-6989.
89. S.M. Roman-Goldstein, P.A. Barnett, C.I. McCormick, J. Szumowski, E.M. Shannon, F.L. Ramsey, M. Mass, and E.A. Neuwelt, Effects of Gd-DTPA after osmotic BBB disruption in a rodent model: Toxicity and MR findings, J Comput Assist Tomogr 18 (1994), 731-736.
90. J. Ruiz-Cabello, P. Walczak, D.A. Kedziorek, V.P. Chacko, A.H. Schmieder, S.A. Wickline, G.M. Lanza, and J.W. Bulte, In vivo "hot spot" MR imaging of neural stem cells using fluorinated nanoparticles, Magn Reson Med 60 (2008), 1506-1511.
91. S. Santra, H. Yang, D. Dutta, J.T. Stanley, P.H. Holloway, W. Tan, B.M. Moudgil, and R.A. Mericle, TAT conjugated, FITC doped silica nanoparticles for bioimaging applications, Chem Commun (Camb) (2004), 2810-2811.
92. L. Schröder, T.J. Lowery, C. Hilty, D.E. Wemmer, and A. Pines, Molecular imaging using a targeted magnetic resonance hyperpolarized biosensor, Science (New York, NY) 314 (2006), 446-449. (Pubitemid 44628961)
93. S. Schwarz, S. Schwab, M. Bertram, A. Aschoff, and W. Hacke, Effects of hypertonic saline hydroxyethyl starch solution and mannitol in patients with increased intracranial pressure after stroke, Stroke 29 (1998), 1550-1555.
94. S. Serres, D.C. Anthony, Y. Jiang, K.A. Broom, S.J. Campbell, D.J. Tyler, S.I. van Kasteren, B.G. Davis, and N.R. Sibson, Systemic inflammatory response reactivates immune-mediated lesions in rat brain, J Neurosci 29 (2009), 4820-4828.
95. E.M. Shapiro, K. Sharer, S. Skrtic, and A.P. Koretsky, In vivo detection of single cells by MRI, Magn Reson Med 55 (2006), 242-249.
96. M. Shapiro, J. Szablowski, R. Langer, and A. Jasanoff, Protein nanoparticles engineered to sense kinase activity in MRI, J Am Chem Soc 131 (2009), 2484-2486.
97. A.D. Sherry and M. Woods, Chemical exchange saturation transfer contrast agents for magnetic resonance imaging, Annu Rev Biomed Eng 10 (2008), 391-411.
98. N.R. Sibson, A.M. Blamire, M. Bernades-Silva, S. Laurent, S. Boutry, R.N. Muller, P. Styles, and D.C. Anthony, MRI detection of early endothelial activation in brain inflammation, Magn Reson Med 51 (2004), 248-252.
99. A.C. Silva, J.H. Lee, I. Aoki, and A.P. Koretsky, Manganese-enhanced magnetic resonance imaging (MEMRI): Methodological and practical considerations, NMR Biomed 17 (2004), 532-543.
100. B. Sitharaman and L.J. Wilson, Gadonanotubes as new high-performance MRI contrast agents, Int J Nanomedicine 1 (2006), 291-295.
101. D.M. Skovronsky, B. Zhang, M.P. Kung, H.F. Kung, J.Q. Trojanowski, and V.M. Lee, In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease, Proc Natl Acad Sci USA 97 (2000), 7609-7614.
102. D.E. Sosnovik, M. Nahrendorf, and R. Weissleder, Magnetic nanoparticles for MR imaging: Agents, techniques and cardiovascular applications, Basic Res Cardiol 103 (2008), 122-130.
103. D.E. Sosnovik and R. Weissleder, Emerging concepts in molecular MRI, Curr Opin Biotechnol 18 (2007), 4-10.
104. D.L.J. Thorek, A.K. Chen, J. Czupryna, and A. Tsourkas, Superparamagnetic iron oxide nanoparticle probes for molecular imaging, Ann Biomed Eng 34 (2006), 23-38.
105. E. Toth, L. Helm, and A.E. Merbach, "Relaxivity of gadolinium(III) complexes: Theory and mechanism, " The chemistry of contrast agents in medical magnetic resonance imaging, A.E. Merbach and E. Toth (Editors), Wiley, New York, 2001.
106. L.H. Treat, N. McDannold, N. Vykhodtseva, Y. Zhang, K. Tam, and K. Hynynen, Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound, Int J Cancer 121 (2007), 901- 907.
107. J.S. Troughton, M.T. Greenfield, J.M. Greenwood, S. Dumas, A.J. Wiethoff, J. Wang, M. Spiller, T.J. McMurry, and P. Caravan, Synthesis and evaluation of a high relaxivity manganese(II)-based MRI contrast agent, Inorg Chem 43 (2004), 6313-6323.
108. S.I. van Kasteren, S.J. Campbell, S. Serres, D.C. Anthony, N.R. Sibson, and B.G. Davis, Glyconanoparticles allow pre-symptomatic in vivo imaging of brain disease, Proc Natl Acad Sci USA 106 (2009), 18-23.
109. N. Vykhodtseva, N. McDannold, and K. Hynynen, Progress and problems in the application of focused ultrasound for blood-brain barrier disruption, Ultrasonics 48 (2008), 279-296.
110. K.M. Ward, A.H. Aletras, and R.S. Balaban, A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST), J Magn Reson 143 (2000), 79-87.
111. R. Weissleder, M. Simonova, A. Bogdanova, S. Bredow, W.S. Enochs, and A. Bogdanov Jr., MR imaging and scintigraphy of gene expression through melanin induction, Radiology 204 (1997), 425-429.
112. E.J. Werner, A. Datta, C.J. Jocher, and K.N. Raymond, High-relaxivity MRI contrast agents: Where coordination chemistry meets medical imaging, Angew Chem Int Ed Engl 47 (2008), 8568-8580.
113. G.L. Wolf and L. Baum, Cardiovascular toxicity and tissue proton T1 response to manganese injection in the dog and rabbit, AJR Am J Roentgenol 141 (1983), 193-197.
114. J.X. Yu, V.D. Kodibagkar, W. Cui, and R.P. Mason, 19F: A versatile reporter for non-invasive physiology and pharmacology using magnetic resonance, Curr Med Chem 12 (2005a), 819-848.
115. X. Yu, Y.Z. Wadghiri, D.H. Sanes, and D.H. Turnbull, In vivo auditory brain mapping in mice with Mn-enhanced MRI, Nat Neurosci 8 (2005b), 961-968.
116. G. Zabow, S. Dodd, J. Moreland, and A. Koretsky, Micro-engineered local field control for high-sensitivity multispectral MRI, Nature 453 (2008), 1058-1063.
117. S. Zhang, M. Merritt, D.E. Woessner, R.E. Lenkinski, and A.D. Sherry, PARACEST agents: Modulating MRI contrast via water proton exchange, Acc Chem Res 36 (2003), 783-790.
118. X.-A. Zhang, K.S. Lovejoy, A. Jasanoff, and S.J. Lippard, Water-soluble porphyrins as a dual-function molecular imaging platform for MRI and fluorescence zinc sensing, Proc Natl Acad Sci USA 104 (2007), 10780- 10785.
119. Y. Zhang and W.M. Pardridge, Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor, J Pharmacol Exp Ther 313 (2005), 1075-1081.
120. M. Zhao and R. Weissleder, Intracellular cargo delivery using tat peptide and derivatives, Med Res Rev 24 (2004), 1-12.
121. O. Zurkiya, A.W. Chan, and X. Hu, MagA is sufficient for producing magnetic nanoparticles in mammalian cells, making it an MRI reporter, Magn Reson Med 59 (2008), 1225-1231.